# case_13_node_3

## Outcome

- Run status: complete; final source: LLM.
- Target: gemcitabine plus tislelizumab rechallenge after CNS progression on tislelizumab maintenance in metastatic squamous NSCLC.
- No direct cutoff-valid evidence was retrieved. The final answer returned low confidence, no citations, and predicted limited benefit/stability mainly from treatment history and model prior.

## Component audit

- Planning correctly asked for the exact regimen, prior PD-1 exposure/rechallenge, 8–12-week response, six-month survival and CNS evidence. However, the direct-evidence step returned no accepted evidence and the second step admitted six weak immunochemotherapy analogs.
- Five of six accepted items were low-relevance analogs: EGFR-mutant nivolumab background, pembrolizumab with pemetrexed/carboplatin, brain oligometastatic multimodal treatment, MET-ex14 sarcomatoid NSCLC pseudoprogression and a perioperative nivolumab case. None answers the target rechallenge question.
- AnswerMemory atomicity held: six items remained six bounded claims.
- Context accurately declared every mismatch and left direct findings empty, but still forwarded all six weak findings. Generate cited none of them, so the retrieval work did not materially support the prediction.
- Runtime remained excessive: nine rerank calls used 489.7 seconds and 74,635 tokens; three Evidence Review calls used 181.7 seconds. Total observed LLM-stage time was roughly 17 minutes before overlap/accounting effects.

## Classification

- General retrieval issue: exact, high-dimensional goals are not progressively relaxed along one dimension at a time; after exact failure the pipeline jumps to broad immunochemotherapy analogs.
- General evidence issue: Evidence Review treats topical relatedness as useful analog support even when regimen, line/rechallenge setting, histology and endpoint all differ.
- Positive behavior: Context and Generate did not convert weak analogs into direct target claims or citations.
- Skill candidate: evidence expansion should follow a controlled ladder—exact regimen/rechallenge, same PD-1 rechallenge with alternate chemotherapy, same histology/regimen class, then mechanistic background—and stop forwarding analogs below a minimum applicability profile.
